NCT02617277 2026-03-04
Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
Clinical Trials
10 trialsNCT03421353 2024-08-21
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT02588105 2022-09-19
AToM
AstraZeneca
Phase 1 Completed
NCT04742036 2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1 Completed
NCT04462952 2022-07-25
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT03150368 2021-10-19
Extended Use of ModraDoc006/r
Modra Pharmaceuticals
Phase 1 Completed
NCT02430311 2019-07-31
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
AstraZeneca
Phase 1 Completed
NCT02341456 2019-03-25
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT02042781 2017-10-09
Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
Zucero Pty Ltd
Phase 1 Completed
NCT01163903 2015-07-15
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
University Health Network, Toronto
Phase 1 Completed